Health Economics›Anal cancer›Metastatic disease first-line therapy

Metastatic disease first-line therapy

Anal cancer · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	7.4 mo	—	11	R 55 338 PFS proxy	1
Cisplatin and Fluorouracil (CF) Variant #29	—	R 1 900	21d	~5.3 mo	~11.5 mo	~8	~R 15 201 PFS proxy · indirect	27
mDCF Variant #01	—	R 1 634	14d	—	~10.2 mo	—	—	1

3 of 3 regimens shown